Theravance Biopharma US, Inc.

We are excited to have Lucy Norcliffe-Kaufmann, Ph.D., rejoin the Theravance Biopharma team! Dr. Norcliffe-Kaufmann brings with her a wealth of knowledge and proven expertise in clinical research and autonomic disorders. Her leadership and expertise will be invaluable as we progress our ampreloxetine program through the CYPRESS pivotal Phase 3 clinical trial and, if results are positive, work towards regulatory approval to bring a potential innovative medicine to patients. We are honored to have her on our team and eager to see all that we will achieve together in pursuit of making a difference in patients’ and caregivers’ lives. Welcome, Lucy!

It was incredible connecting at the 10th Annual Congress of the European Academy! Thank you @European Academy of Neurology #neurology #HomeOfNeurology #EANeurology #10yearsEAN

Theravance Biopharma will be attending the 10th Annual Congress of the European Academy of Neurology! #ean2024 brings together national neurological societies, individual neurologists and related scientists to speak with one united voice and attracts more than 6,000 delegates each year. We look forward to seeing you there! @European Academy of Neurology #neurology #HomeOfNeurology #EANeurology #10yearsEAN

Theravance Biopharma is researching an investigational drug aiming to reduce nOH symptoms in people with MSA. Symptoms of nOH frequently impact one’s ability to conduct routine daily activities, especially those requiring standing or walking. Learn more about the Phase 3 CYPRESS study and if it’s right for you by visiting our study website at www.cypress-study.com.

ICYMI: The virtual event hosted by Theravance Biopharma US, Inc. (#TBPH) is now available for replay! The event features Horacio Kaufmann, MD, FAAN (New York University Grossman School of Medicine) and Italo Biaggioni, MD (Vanderbilt Autonomic Dysfunction Center), who discuss the unmet need and current treatment landscape for MSA patients with symptomatic nOH. Watch here: https://bit.ly/3wRvQZ9

Spring into action this May! Symptomatic nOH is a common yet debilitating occurrence in people with MSA. The condition affects approximately 70-90% of those with MSA, with symptoms such as dizziness when transitioning from sitting to standing having a potentially significant impacting quality of life. If you or someone you know diagnosed with MSA experience symptoms of nOH, you may quality to participate in our actively recruiting Phase 3 CYPRESS Study. To learn more, including locations of study centers, please visit our study website at cypress-study.com.

Tune into the virtual KOL event at 10am ET hosted by Theravance Biopharma US, Inc. (#TBPH) featuring important presentations from industry experts and company management on ampreloxetine’s potential for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy. Register here: https://bit.ly/3wRvQZ9

On this Clinical Trials Day, let's honor the countless individuals who selflessly dedicate themselves to the advancement of medical science: the participants. Their willingness to step forward, often in the face of uncertainty, embodies the very essence of courage and altruism. Each participant's journey is marked by resilience, hope, and a deep-seated belief in the power of research to transform lives. Today, we express our heartfelt gratitude for their invaluable contributions to the pursuit of knowledge and the betterment of humanity.

Happy International Nurses Day! Today, we celebrate the invaluable contributions of nurses who tirelessly work to promote health, prevent illness, and provide comfort to those in need. Their kindness, expertise, and selflessness shine brightly, guiding patients and their families through moments of vulnerability with care and compassion. Let's express our heartfelt gratitude nurses everywhere for always helping those in need.

Don’t miss it! Theravance Biopharma US, Inc. (#TBPH) is hosting a virtual KOL event on Thurs. May 23 at 10am ET, including presentations from Company management on the clinical development program for ampreloxetine, an investigational, once-daily norepinephrine reuptake inhibitor with the potential to be a first-in-class therapy effective in treating a constellation of cardinal symptoms of nOH in MSA patients. Register here: https://brnw.ch/21wJvrv